Lv3
366 积分 2023-10-17 加入
Unmet needs in maintenance therapy for extensive stage small cell lung cancer
11小时前
待确认
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review
7天前
已完结
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer
7天前
已完结
Small Cell Lung Cancer
8天前
已完结
Small cell lung cancer
8天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
15天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
15天前
已完结
OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)
15天前
已完结
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity
16天前
已完结
OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
16天前
已完结
皖公网安备34019202002308
